KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EBITDA (2016 - 2025)

Historic EBITDA for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $133.8 million.

  • Charles River Laboratories International's EBITDA rose 1396.36% to $133.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.9 million, marking a year-over-year decrease of 7330.93%. This contributed to the annual value of $227.3 million for FY2024, which is 6316.84% down from last year.
  • Latest data reveals that Charles River Laboratories International reported EBITDA of $133.8 million as of Q3 2025, which was up 1396.36% from $100.1 million recorded in Q2 2025.
  • In the past 5 years, Charles River Laboratories International's EBITDA registered a high of $187.4 million during Q2 2022, and its lowest value of -$167.7 million during Q4 2024.
  • In the last 5 years, Charles River Laboratories International's EBITDA had a median value of $148.8 million in 2022 and averaged $126.0 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 7917.62% in 2021, then tumbled by 22615.44% in 2024.
  • Charles River Laboratories International's EBITDA (Quarter) stood at $172.8 million in 2021, then fell by 5.21% to $163.8 million in 2022, then fell by 18.86% to $132.9 million in 2023, then plummeted by 226.15% to -$167.7 million in 2024, then skyrocketed by 179.79% to $133.8 million in 2025.
  • Its last three reported values are $133.8 million in Q3 2025, $100.1 million for Q2 2025, and $74.7 million during Q1 2025.